Quick Answer
BioLineRx Ltd. reported R&D Expense of $8.09 million for fiscal year 2025.
BioLineRx Ltd. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $8.09M | -11.5% |
| 2024 | $9.15M | -26.9% |
| 2023 | $12.52M | -29.0% |
| 2022 | $17.63M | -9.4% |
| 2021 | $19.47M | +7.1% |
| 2020 | $18.17M | -22.5% |
| 2019 | $23.44M | +18.3% |
| 2018 | $19.81M | +1.5% |
| 2017 | $19.51M | +74.6% |
| 2016 | $11.18M | -2.7% |
| 2015 | $11.49M | — |
- BioLineRx Ltd. showed a decrease of -11.5% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, BioLineRx Ltd.’s r&d expense has declined by 29.6% (from $11.49 million to $8.09 million).
- The most recent figure is from BioLineRx Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: